Josh Veatch

Starting a lab developing T cell immunotherapy of solid tumors @fredhutch

[Josh Veatch @joshrveatch]

@CterminiPhD Looking forward to reaching that stage…

[Josh Veatch @joshrveatch]

Definitely the last time it will be this clean

[Josh Veatch @joshrveatch]

Ready to move in to the new lab

[Chrystal Paulos @Chrystal_Paulos]

💥Cheers to ⁦Anna Cole @AnnaCamille98 in ⁦@PaulosLab⁩ ⁦@WinshipAtEmory⁩ on her exceptional talk on the unexpected role of host B cells on augmenting adoptively transferred Th17 cells⁩ against melanoma ⁦@sitcancer⁩ #SITC2022!

[Journal of Experimental Medicine @JExpMed]

Boieri, @CaImmunoprevent et al. demonstrate that CD4+ T helper cells directly block #breastcancer development by forcing the cancer cells to terminally differentiate. https://t.co/ykzBgS4ZsR

From our #Cancer #Immunotherapy collection: https://t.co/vZLDRiauiJ

#SITC22

[Ming Li @MingLiLab]

Tumor-associated macrophages present cancer cell antigen and drive cytotoxic T cell exhaustion. Check out our story from brilliant Briana Nixon, @dkuo @arihakimi and collaborators https://t.co/oKOKlO4F8S

[Josh Veatch @joshrveatch]

Shout out to my wonderful wife for catching up to me with 8 miles left and dragging me across the finish line, and also keeping me out of the medical tent.

[Josh Veatch @joshrveatch]

Did the Victoria marathon today. It appears my optimal running distance is not a full marathon, much prefer the halfs.

[Dr. Patrick Hwu @PatrickHwuMD]

Tumor infiltrating lymphocytes (TIL) are immune cells found in tumors that can be expanded in the lab then reinfused into patients. This is the first randomized trial showing a benefit of #TILTherapy in patients with advanced #melanoma. #ESMO22 https://t.co/XvJKqMkjvn

[Jason Luke, MD, FACP, FASCO @jasonlukemd]

Mind blown by @SWOG 1801. Congrats @DrSapnaPatel @EladSharonMD et al! Thinking ~ this all day & really wondering if should give 1 dose PD1+low dose ipi to all pt's w T3b/T4 #melanoma or clin + node bf resect. We need a trial PD1+ipi neoadj then STOP vs neo + adj PD1 ASAP! #ESMO22

[Josh Veatch @joshrveatch]

Missed the experience of post call encephalopathy so reliving it for an overnight road race relay #HoodToCoast

[Josh Veatch @joshrveatch]

6 year old getting in on the action

[Josh Veatch @joshrveatch]

10 year old daughter making material for the lab website

[Josh Veatch @joshrveatch]

When she starts mixing in endorsements of specific drugs to her comics I’ll know she’s supplementing her allowance

[Carl Pierce, MD, PhD @carlpierce]

“You wrote in your IACUC protocol that the studies would be carried out BY mice. Did you mean to write IN mice?”

“No”

[Josh Veatch @joshrveatch]

@ElizSMcKenna @RealAhmedDiab Hi Liz, I’m a new PI at the Fred hutch in Seattle studying CD4 T cells in cancer immunity

[Anusha Kalbasi @xrtcell]

What’s your fav gamma chain cytokine? With #SynBio from Leon Su/Chris Garcia lab and also co-led with Mikko Siurala/@carlhjune lab, we show in @nature that synthetic IL9R signaling endows #tcells w superior properties for cancer therapy @ToniRibas12 https://t.co/XQ6YoXhu2X

[Josh Veatch @joshrveatch]

@roneymsi It is a small number of patients but we think the non responders did not benefit because their tumors were hidden from the T cells because of class I MHC down regulation.

[Josh Veatch @joshrveatch]

The goal of this study was to see whether we could overcome resistance to PD-1 inhibitors in patients with metastatic merkel cell carcinoma by giving TCR transgenic tumor specific T cells

[Fred Hutch Cancer Center @fredhutch]

Dr. @joshrveatch is presenting "Merkel polyoma virus specific T cell receptor transgenic T cell therapy in PD-1 inhibitor refractory #Merkelcellcarcinoma" at #ASCO22. https://t.co/nWO2qtUmG4

[Josh Veatch @joshrveatch]

The trial is open to patients with merkel cell carcinoma that is resistant to PD-1 inhibitors, and patients need to be virus positive and have HLA-A02. It requires coming to Seattle for treatment but the screening tests can be done remotely.

[Josh Veatch @joshrveatch]

We are now enrolling in a new version of the trial which uses interferon gamma in combination with T cells as a strategy to upregulate class I MHC and see whether this allows the T cells to see the tumor and lead to benefit in more patients.